论文部分内容阅读
目的探讨匹多莫德联合孟鲁司特片治疗小儿支气管哮喘的临床疗效。方法选取2013年1月—2014年1月安阳市妇幼保健院收治的小儿支气管哮喘患儿88例,随机分为对照组与治疗组,各44例。对照组患儿予以孟鲁司特片治疗,治疗组患儿在对照组基础上予以匹多莫德治疗。观察两组患儿临床疗效、发作次数、发作持续时间、肺功能指标〔用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气峰流速(PEF)〕及治疗前后免疫功能指标(Ig A、Ig G、Ig M)改善情况。结果治疗组患儿总有效率高于对照组,发作次数少于对照组,发作持续时间短于对照组,FVC、FEV1、PEF高于对照组,差异有统计学意义(P<0.05);治疗前两组患儿Ig A、Ig G、Ig M水平比较,差异无统计学意义(P>0.05),治疗后治疗组患儿Ig A、Ig G、Ig M水平高于对照组,差异有统计学意义(P<0.05)。结论匹多莫德联合孟鲁司特片治疗小儿支气管哮喘的临床疗效显著,可提高患儿的免疫功能,改善患儿肺功能,减少疾病复发。
Objective To investigate the clinical efficacy of pidotimod combined with montelukast tablets in children with bronchial asthma. Methods From January 2013 to January 2014, 88 children with bronchial asthma admitted to Anyang MCH Hospital were randomly divided into control group and treatment group, 44 cases in each group. Children in the control group were treated with montelukast tablets. The children in the treatment group were treated with pidotimod on the basis of the control group. The clinical efficacy, number of seizures, duration of seizure, pulmonary function indexes (FVC, FEV1, PEF) and immune function before and after treatment were observed in both groups. (Ig A, Ig G, Ig M). Results The total effective rate of treatment group was higher than that of control group, the number of attack was less than that of control group, the duration of attack was shorter than that of control group, FVC, FEV1 and PEF were higher than that of control group (P <0.05) The levels of Ig A, Ig G and Ig M in the first two groups were not significantly different (P> 0.05). The levels of Ig A, Ig G and Ig M in the treatment group were higher than those in the control group Significance (P <0.05). Conclusion Pidotimod combined montelukast tablets in children with bronchial asthma clinical significant effect, can improve children’s immune function, improve children’s lung function and reduce disease recurrence.